Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | The Hokusai VTE-Cancer Study: the importance of improving VTE treatment

Harry Buller • 10 Dec 2017
ASH 2017
General Edoxaban Heparin
HOKUSAI-VTE

Venous thromboembolism (VTE) remains a major risk for patients with cancer. The current standard of care for VTE includes subcutaneously injecting low-molecular-weight heparin (LMWH), which has shown to be effective; however, patients are required to use this treatment for prolonged periods. In this interview, recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Harry Buller, MD, PhD, of the Academic Medical Centre, Amsterdam, Netherlands, discusses the issues surrounding VTE. Prof. Buller also explains the reasoning behind the Hokusai VTE-Cancer Study (NCT02073682), which compared subcutaneous injection of LMWH vs. oral edoxaban for the treatment of VTE.

More from Harry Buller

1:02
Next steps in VTE treatment: will oral edoxoban replace the current standard of care?
Harry Buller • 10 Dec 2017
3:55
The Hokusai VTE-Cancer Study: objectives and design
Harry Buller • 10 Dec 2017

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals